FINWIRES · TerminalLIVE
FINWIRES

Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says

By

Adlai Nortye (ANL) stands to benefit from the GSK (GSK)-Hutchmed (HCM) deal, which validates growing interest in targeted KRAS therapies, Oppenheimer said in a note emailed Friday.

Hutchmed said Thursday its unit licensed rights to GSK to develop and commercialize experimental cancer treatment HMPL-A830 outside Greater China.

HMPL-A830 is an EGFR-targeted antibody-drug conjugate carrying a KRAS inhibitor payload. The deal highlights increasing interest in targeted approaches that aim to improve the therapeutic index of RAS-pathway inhibition, Oppenheimer analysts said.

Adlai Nortye's approach is differentiated, with AN9025 already in the clinic and data expected in H1 2027. AN4035 uses a pan-RAS(ON) inhibitor payload with a CEACAM5-targeting antibody, which could provide advantages in breadth, durability, and target selection, the analysts added.

The deal should improve "investor awareness of comparable RAS-focused platforms and reinforce the strategic value embedded within Adlai Nortye's differentiated RAS franchise," the analysts said.

Oppenheimer has an outperform rating and a $32 price target on Adlai Nortye.

Price: $15.14, Change: $+0.39, Percent Change: +2.64%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT